Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | YARS1 | P54577 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9513983 | 1.00 | SLC7A5 (0.51) | SLC7A5YARS1OPRD1OPRM1OPRK1 | |
| SCHEMBL30863567 | 0.91 | OPRD1 (0.51) | OPRD1OPRM1OPRK1 | |
| SCHEMBL29462561 | 0.89 | SLC7A5 (0.59) | SLC7A5YARS1OPRD1OPRM1OPRK1 | |
| SCHEMBL29531284 | 0.89 | SLC7A5 (0.59) | SLC7A5YARS1OPRD1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL30698094 | 0.87 | SLC7A5 (0.58) | SLC7A5YARS1OPRD1OPRM1OPRK1 | |
| SCHEMBL20990366 | 0.87 | OPRD1 (0.58) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31276527 | 0.86 | SLC7A5 (0.56) | SLC7A5YARS1OPRD1OPRM1OPRK1 | |
| SCHEMBL5686804 | 0.84 | OPRD1 (0.54) | OPRD1OPRM1OPRK1 | |
| SCHEMBL22644029 | 0.84 | OPRD1 (0.55) | SLC7A5YARS1OPRD1OPRM1OPRK1 | |
| SCHEMBL31265324 | 0.84 | OPRD1 (0.56) | SLC7A5YARS1OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099554-A1 | COMPOSITIONS AND METHODS OF FAS INHIBITION | ONL THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| EP-4370208-A2 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240156898-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4355349-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023287794-A2 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022266127-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | ONL THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-5354675-A | Amidation of glycine | SHISEIDO COMPANY LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0447547-B1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO CO LTD (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0447547-A1 | C-TERMINUS AMIDATION ENZYME COMPOSITION, PROCESS FOR ITS PREPARATION AND ITS USE | SHISEIDO COMPANY LIMITED (JP) | 1991-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | PDE6C, UACA, EYA3 | SLC7A5 570/4885YARS1 3328/4885OPRD1 4615/4885 |
| US-20240156898-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS AND DISEASES | UACA, ASAH2, NFKBIA | SLC7A5 4763/4885YARS1 3155/4885OPRD1 4411/4885 |
| US-20250099554-A1 | COMPOSITIONS AND METHODS OF FAS INHIBITION | CFB, BAX, FASN | SLC7A5 4772/4885YARS1 3383/4885OPRD1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.